Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development

Patent metadata

Field	Value
Publication number	US-9791444-B2
Application number	US-201113640989-A
Country	US
Kind code	B2
Filing date	Apr 15, 2011
Priority date	Apr 16, 2010
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

The invention relates to a method for quantitatively identifying relevant HLA-bound peptide antigens from primary tissue specimens on a large scale without labeling approaches. This method can not only be used for the development of peptide vaccines, but is also highly valuable for a molecularly defined immunomonitoring and the identification of new antigens for any immunotherapeutic strategy in which HLA-restricted antigenic determinants function as targets, such as a variety of subunit vaccines or adoptive T-cell transfer approaches in cancer, or infectious and autoimmune diseases.

First claim

The invention claimed is:

1. A method for identification and label-free quantification of at least one MHC ligand peptide on a primary tissue sample, comprising:
a) providing at least one diseased primary tissue sample and at least one sample of primary healthy tissue optionally corresponding to diseased tissue,
b) isolating one or more label-free MHC ligand peptides from said samples,
c) performing an HPLC-MS analysis on said label-free MHC ligand peptides,
d) extracting a precursor ion signal intensity area for each signal, as derived from c),
e) identifying one or more sequences of said label-free MHC ligand peptides by fragment spectra clustering and database search, in order to group areas between different runs and samples, and normalizing areas within replicate runs to compensate technical performance and/or sensitivity differences between replicate runs resulting in average quantities for each peptide per sample including error estimates,
f) Assigning said sequences to MHC alleles in order to generate allele-specific sequence subgroups for a comparison between different samples, and normalizing between different samples using allele-specific subgroups to account for different sample sizes or MHC expression levels wherein a result is relative quantities comparable between samples,
g) performing a data quality control based on peptide reproducibility for every sample, verifying that a total number of identified sequences and a number of sequences with small variances in areas is as high as possible,
h) calculating presentation profiles and scores in order to determine a potential overpresentation of MHC ligand peptides,
i) controlling a quality of identifications and area estimates, optionally by visual inspection of peptide identification results and of area reproducibilities, or statistical analysis,
j) comparing value detected in said at least one diseased primary tissue sample with the value obtained from said at least one primary healthy tissue, and
k) quantifying said label-free MHC ligand peptide.

2. The method according to claim 1 , wherein said at least one label-free MHC ligand peptide comprises a tumor associated peptide (TAA) or disease associated peptide (DAA).

3. The method according to claim 1 , further comprising a selection of overrepresented and/or tumor-specific MHC ligand peptides.

4. The method according to claim 1 , wherein said diseased sample is a tumor sample or a sample of infected tissue.

5. The method according to claim 1 , wherein controlling quality is performed using an automate and/or by manual inspection.

6. The method according to claim 1 , further comprising at least one step selected from the group consisting of: in d) aligning the retention time to assign corresponding signals within replicate runs without a knowledge about sequences, and/or assigning corresponding signals between different samples by retention time alignment without knowledge about sequences, in h) implementing relative presentation data from more than one peptide per gene to calculate a gene-centered over-presentation score, and in i) performing a quality control based on a spiked peptide.

7. The method according to claim 1 , wherein said method is performed in vitro.

8. The method according to claim 1 , wherein said method is performed in the order as indicated.

9. The method according to claim 1 , wherein said method consists of the steps as indicated.

10. The method according to claim 1 , further comprising synthesizing said at least one MHC ligand peptide as identified and/or quantified by said method on a synthesizer and/or manually.

11. The method according to claim 10 , further comprising testing said synthesized MHC ligand peptide for immunogenicity.

12. The method according to claim 1 , wherein said sample is derived from one individual.

13. The method according to claim 12 , further comprising generating a personalized MHC ligand profile, optionally a personalized disease-specific MHC ligand profile, based on said MHC ligand peptides as identified and/or quantified.

14. The method according to claim 1 , wherein said total number of identified sequences and number of sequences with small variances in areas is higher than 5, optionally higher than 25.

Assignees

• Weinschenk Toni
• Fritsche Jens
• Immatics Biotechnologies Gmbh

Inventors

• Weinschenk Toni
• Fritsche Jens

Classifications

• G01N33/6842 Primary

  Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins · CPC title

• G01N33/6878

  in epitope analysis · CPC title

• G01N2333/70539

  MHC-molecules, e.g. HLA-molecules · CPC title

• G01N33/56977 Primary

  HLA or MHC typing · CPC title

• G01N33/6848

  Methods of protein analysis involving mass spectrometry · CPC title